EMA Authorised: Anoro Ellipta (previously Anoro) (umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA authorised Anoro Ellipta (umeclidinium bromide and vilanterol trifenatate) for chronic obstructive pulmonary disease, with GlaxoSmithKline Trading Servi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Anoro Ellipta (umeclidinium bromide; vilanterol trifenatate)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 28/07/2025